Related Experiment Video
Updated: Sep 21, 2025
A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
Published on: July 9, 2020
Mir-22-incorporated polyelectrolyte coating prevents intima hyperplasia after balloon-induced vascular injury
Jia-Yin Fu1, Yu-Xian Lai2, Si-Si Zheng1
1Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China. jyulu@zju.edu.cn.
Abstract:
Drug-coated balloons (DCBs) offer potential to deliver drugs to treat coronary lesions but without leaving permanent implants behind. Paclitaxel and sirolimus are anti-proliferation drugs that are commonly used in commercially available DCBs. However, these drugs present significant cytotoxicity concern and low efficacy in vivo. Here, we use microRNA-22 (miR-22) as balloon loaded drugs and polyelectrolyte complexes (PECs) polyethyleneimine/polyacrylic acid (PEI/PAA) as balloon coatings to establish a new DCB system through the ultrasonic spray method. The PEI/PAA forms a stable and thin coating on the balloon, which resulted in a good transfer capacity to the vessel wall both in vitro and in vivo. miR-22 that could modulate smooth muscle cell (SMC) phenotype switching is incorporated into the PEI/PAA coating and shows a sustained release profile. The PEI/PAA/miR-22 coated balloon successfully inhibits intima hyperplasia after balloon-induced vascular injury in a rat model through decreasing proliferative SMCs via the miR-22-methyl-CpG binding protein 2 (MECP2) axis. Our findings indicate that balloons coated with PEI/PAA/miR-22 have great potential to be promising DCBs in the treatment of cardiovascular disease.
Insights
This study introduces a novel drug-coated balloon (DCB) using microRNA-22 (miR-22) and a polyelectrolyte complex coating. This new DCB system effectively inhibits vascular hyperplasia by modulating smooth muscle cell behavior.
Area of Science:
- Biomaterials Science
- Cardiovascular Research
- Nanotechnology
Background:
- Drug-coated balloons (DCBs) treat coronary lesions without permanent implants.
- Current DCBs use paclitaxel or sirolimus, facing cytotoxicity and low in vivo efficacy concerns.
Purpose of the Study:
- To develop a novel DCB system using microRNA-22 (miR-22) and a polyethyleneimine/polyacrylic acid (PEI/PAA) polyelectrolyte complex (PEC) coating.
- To evaluate the efficacy of the PEI/PAA/miR-22 coated balloon in inhibiting neointima hyperplasia in a rat vascular injury model.
Main Methods:
- A new DCB system was created using ultrasonic spray deposition of PEI/PAA PECs loaded with miR-22 onto balloons.
- The coating's stability, transfer capacity, and miR-22 release profile were assessed in vitro and in vivo.
- The therapeutic effect was evaluated in a rat model of balloon-induced vascular injury.
Main Results:
- The PEI/PAA coating provided stable and efficient drug transfer to the vessel wall.
- Sustained release of miR-22 was achieved from the PEI/PAA coating.
- The PEI/PAA/miR-22 coated balloon significantly inhibited intima hyperplasia by reducing proliferative smooth muscle cells via the miR-22-MECP2 pathway.
Conclusions:
- The PEI/PAA/miR-22 coated balloon represents a promising alternative to conventional DCBs.
- This novel DCB system shows potential for treating cardiovascular diseases by effectively managing vascular remodeling.
More Related Videos
09:41Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
Published on: December 23, 2014
07:02A Rabbit Venous Interposition Model Mimicking Revascularization Surgery using Vein Grafts to Assess Intimal Hyperplasia under Arterial Blood Pressure
Published on: May 15, 2020
